Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Arqt save search
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
Published: 2024-01-22 (Crawled : 13:00) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 5.85%
H: 7.56%
C: 2.91%
zoryve dermatitis treatment
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
Published: 2023-12-15 (Crawled : 22:00) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
| Email alert
Add to watchlist
zoryve fda dermatitis treatment
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.49%
H: 9.76%
C: -7.32%
fda drug children dermatitis treatment application
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
Published: 2023-10-06 (Crawled : 12:00) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 1.13%
H: 5.97%
C: 4.69%
zoryve fda children psoriasis treatment
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
Published: 2023-09-19 (Crawled : 12:00) - arcutis.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: -1.09%
H: 4.09%
C: 2.67%
children dermatitis positive treatment trial results
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
Published: 2023-09-12 (Crawled : 12:00) - arcutis.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.13%
H: 6.67%
C: 5.0%
fda drug children dermatitis treatment application
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
Published: 2023-09-07 (Crawled : 12:00) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 4.52%
H: 0.85%
C: -6.54%
dermatitis favorable positive treatment results
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
Published: 2023-05-02 (Crawled : 12:00) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: -1.04%
H: 1.05%
C: -0.21%
children dermatitis treatment trial
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
Published: 2023-04-28 (Crawled : 22:00) - biospace.com/
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.07%
H: 2.9%
C: 0.51%
approval psoriasis treatment
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
Published: 2023-04-18 (Crawled : 14:00) - biospace.com/
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.93%
H: 1.06%
C: -2.06%
fda drug dermatitis treatment application
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
Published: 2023-02-21 (Crawled : 15:00) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: -0.82%
H: 0.77%
C: -3.86%
treatment fda drug application dermatitis
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
Published: 2022-12-19 (Crawled : 15:20) - biospace.com/
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: -0.75%
H: 1.01%
C: -7.01%
zoryve treatment drug children application psoriasis
Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older
Published: 2022-08-10 (Crawled : 14:20) - biospace.com/
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.64%
H: 2.84%
C: -0.56%
treatment psoriasis plague
CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
Published: 2022-05-25 (Crawled : 15:00) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: -0.68%
H: 1.27%
C: -11.11%
treatment care dermatitis
National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments
Published: 2022-03-22 (Crawled : 12:30) - arcutis.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 1.15%
H: 6.95%
C: 6.53%
psoriasis treatment
Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.56%
H: 0.24%
C: -1.54%
new drug psoriasis treatment fda drug application plague
Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis
Published: 2021-08-25 (Crawled : 14:00) - biospace.com/
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.05%
H: 3.88%
C: 1.31%
treatment potential phase 3 trial psoriasis enroll
Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
Published: 2021-07-12 (Crawled : 12:15) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 4.75%
H: 2.8%
C: 2.31%
treatment potential dermatitis phase 3 trial enroll
Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo
Published: 2021-07-01 (Crawled : 11:00) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: -2.93%
H: 3.16%
C: 0.04%
treatment phase 2 potential trial phase 2b
Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years
Published: 2021-04-12 (Crawled : 13:15) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.04%
H: 3.83%
C: 1.76%
treatment potential dermatitis phase 3 trial atopic dermatitis
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.